|Print Page Close Window|
AveXis Appoints Sean P. Nolan as Chief Executive Officer
DALLAS, June 18, 2015 — AveXis, Inc., a leading gene therapy company developing treatments for rare and life-threatening genetic diseases, today announced the appointment of Sean P. Nolan as Chief Executive Officer. He will oversee all functions at AveXis, including clinical, regulatory, finance, operations, sales and marketing, manufacturing and quality assurance. He also will join the company’s Board of Directors. Previously, Mr. Nolan was the Chief Business Officer at InterMune.
Mr. Nolan joins AveXis as the company is nearing completion of its fully-enrolled Phase 1 clinical trial in patients with spinal muscular atrophy (SMA). A rare genetic disease, SMA is the most common cause of infant mortality and the second-most common autosomal recessive genetic disorder.
At InterMune (acquired by Roche), an orphan disease company focused on specialty fibrotic disorders, Mr. Nolan led multiple functions across the organization, including North American commercial operations, global marketing, corporate and business development, and global manufacturing/supply chain. He also was responsible for planning and executing the U.S. launch of the company’s novel treatment for idiopathic pulmonary fibrosis, a rare and fatal lung disease with no approved or effective treatments. Prior to that, he held executive positions at Reata Pharmaceuticals and at Ovation Pharmaceuticals (acquired by Lundbeck HS), a company focused on orphan neurology diseases. Earlier in his career, he held key management positions at Abbott, including several years in its neuroscience franchise.
About AveXis, Inc.
© AveXis, Inc. All Rights Reserved.